112 related articles for article (PubMed ID: 2160147)
1. Transmission of human parvovirus B19 by coagulation factor concentrates.
Williams MD; Cohen BJ; Beddall AC; Pasi KJ; Mortimer PP; Hill FG
Vox Sang; 1990; 58(3):177-81. PubMed ID: 2160147
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
[TBL] [Abstract][Full Text] [Related]
3. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
4. Parvovirus B19 transmission by heat-treated clotting factor concentrates.
Blümel J; Schmidt I; Effenberger W; Seitz H; Willkommen H; Brackmann HH; Löwer J; Eis-Hübinger AM
Transfusion; 2002 Nov; 42(11):1473-81. PubMed ID: 12421221
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
[TBL] [Abstract][Full Text] [Related]
7. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates.
Bartolomei Corsi O; Azzi A; Morfini M; Fanci R; Rossi Ferrini P
J Med Virol; 1988 Jun; 25(2):165-70. PubMed ID: 2839609
[TBL] [Abstract][Full Text] [Related]
8. [Parvovirus B19 infection in patients with congenital blood coagulation disorders].
Aguilar Franco C; Lucía Cuesta JF; Ferrer Torres J; Omeñaca Teres M
Med Clin (Barc); 1997 May; 108(17):641-6. PubMed ID: 9312580
[TBL] [Abstract][Full Text] [Related]
9. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2.
Schneider B; Becker M; Brackmann HH; Eis-Hübinger AM
Thromb Haemost; 2004 Oct; 92(4):838-45. PubMed ID: 15467916
[TBL] [Abstract][Full Text] [Related]
10. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation.
Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB;
Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
[TBL] [Abstract][Full Text] [Related]
12. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
13. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.
Azzi A; Ciappi S; Zakvrzewska K; Morfini M; Mariani G; Mannucci PM
Am J Hematol; 1992 Mar; 39(3):228-30. PubMed ID: 1312304
[TBL] [Abstract][Full Text] [Related]
14. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
[TBL] [Abstract][Full Text] [Related]
15. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening.
Soucie JM; De Staercke C; Monahan PE; Recht M; Chitlur MB; Gruppo R; Hooper WC; Kessler C; Kulkarni R; Manco-Johnson MJ; Powell J; Pyle M; Riske B; Sabio H; Trimble S;
Transfusion; 2013 Jun; 53(6):1217-25. PubMed ID: 22998193
[TBL] [Abstract][Full Text] [Related]
17. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.
Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A
J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819
[TBL] [Abstract][Full Text] [Related]
18. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.
Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP
Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of human parvovirus B19 infection in Sao Tomé and Principe, Malawi and Mascarene Islands.
Schwarz TF; Gürtler LG; Zoulek G; Deinhardt F; Roggendorf M
Zentralbl Bakteriol; 1989 Jul; 271(2):231-6. PubMed ID: 2550018
[TBL] [Abstract][Full Text] [Related]
20. Parvovirus B19 antibodies in immunocompromized children in Thailand.
Suandork P; Theamboonlers A; Likitnukul S; Hirsch P; Poovorawan Y
Asian Pac J Allergy Immunol; 2000 Sep; 18(3):161-4. PubMed ID: 11270472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
